Global Esophageal
Cancer Drugs Market, By Therapy Type (Chemotherapy (Docetaxel, Irinotecan,
Trifluridine and Tipiracil, Carboplatin and Paclitaxel, Cisplatin and
5-fluorouracil, and Cisplatin with Capecitabine), Targeted Drug Therapy (Trastuzumab
and Ramucirumab), and Immunotherapy (Pembrolizumab)), By Disease Indication
(Adenocarcinomas, Gastrointestinal Stromal Tumors, Carcinoid Tumors, Squamous
Cell Carcinoma, and Others), By Distribution Channel (Hospital Pharmacy, Retail
Pharmacy, and Online Pharmacy), and By Region (North America, Latin America,
Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 765.2
million in 2018 and is projected to exhibit a CAGR of 8.2% over the
forecast period (2019 - 2027), as highlighted in a new report published by.
Increasing cancer research, Food
and Drug Administration (FDA) approvals-based drug discovery, and rising number
of development programs and pipeline drugs among others are the major factors
that are expected to drive growth of the esophageal cancer drugs market.
Various pharmaceutical companies are focused on research and development of
novel drug therapies for the treatment of esophageal cancer drugs. For
instance, in November 2018, Merck & Co., Inc. revealed the results of phase
3 clinical trial of Keytruda (pembrolizumab), which indicates Keytruda reduced
the risk of death compared to chemotherapy in patients with squamous cell
carcinoma or adenocarcinoma. The overall survival rate of patients who consumed
pembrolizumab was 43% whereas patients who consumed chemotherapy drugs such as
paclitaxel, docetaxel or irinotecan experienced 20% survival rate.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/3036
Manufacturers in the esophageal
cancer drugs market are focusing on increasing product portfolio by receiving
Food and Drug Administration (FDA) approvals to further boost the esophageal
cancer drug market size. In April 2014, FDA approved Cyramza (ramucirumab) for
use in combination with paclitaxel for the treatment of patients with advanced
gastric or gastro-esophageal junction adenocarcinoma.
Browse 38 Market Data Tables and
27 Figures spread through 166 Pages and in-depth TOC on "Esophageal Cancer
Drugs Market, By Therapy Type (Chemotherapy (Docetaxel, Irinotecan, Trifluridine
and Tipiracil, Carboplatin and Paclitaxel, Cisplatin and 5-fluorouracil, and
Cisplatin with Capecitabine), Targeted Drug Therapy (Trastuzumab and
Ramucirumab), and Immunotherapy (Pembrolizumab)), By Disease Indication
(Adenocarcinomas, Gastrointestinal Stromal Tumors, Carcinoid Tumors, Squamous
Cell Carcinoma, and Others), By Distribution Channel (Hospital Pharmacy, Retail
Pharmacy, and Online Pharmacy), and By Region (North America, Latin America,
Europe, Asia Pacific, Middle East, and Africa)
Many companies such as Pfizer
Inc., Merck & Co., Bristol-Meyer Squibb, and Eli Lilly & Company are
focused on drugs that are under development in the pipeline such as Ipilimumab
and Nivolumab and are expected to be launched in the near future. For instance,
in 2018, Bristol-Meyer Squibb’s Opdivo (Nivolumab) intravenous infusion
injection and Yervoy Injection was in the developmental pipeline. It is in
phase III for treatment of stomach cancer and is expected to launch in the
U.S., Europe, South Korea, and Taiwan in the near future
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/esophageal-cancer-drugs-market-3036
Key Takeaways of the Esophageal
Cancer Drugs Market:
The global esophageal cancer
drugs market is expected to expand at a CAGR of 8.2% during the forecast period
(2019–2027), owing to increasing research & development and demand for
genomic and repertoire sequencing-based research
Among therapy type, the
immunotherapy segment is expected to account for maximum share over the
forecast period. For instance, in 2017, pembrolizumab (Keytruda) was approved
by the U.S. Food and Drug Administration (FDA) to treat gastroesophageal cancer
in some patients whose previous treatment did not work or stopped working, and
it was proved to be better than chemotherapy.
Major players operating in the
global esophageal cancer drugs market include Amgen Inc., Eli Lilly and
Company, F. Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer
Ingelheim GmbH, Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG,
Johnson & Johnson, Gilead Sciences, Genentech, Inc., Sanofi-Aventis, and
Merck & Co.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/3036
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment